
The Weight-Loss Shots Semaglutide and Tirzepatide: Controversy and Understanding their Use
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
-
Narrado por:
-
De:
Acerca de esta escucha
This presentation is on the medications semaglutide and tirzepatide , prescribed under brand names such as Ozempic, Wegovy and Monjaro, and others, some of which are in development. These drugs are GLP-1 agonist medications most commonly used for the treatment of type 2 diabetes, but more recently it’s been in the spotlight as a medication for weight loss, causing controversy, misunderstanding, questions and significant shortages of the medication.
Dr. DeSarbo will briefly look at these medications from all perspectives including their use in diabetes, as a weight loss drug for the medical definition of obesity, and their potential impact and fallout with the eating disorder population.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones